Research programme: istiratumab companion diagnostic - Merrimack Pharmaceuticals
Latest Information Update: 19 May 2015
At a glance
- Originator Merrimack Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Pancreatic cancer; Solid tumours
Most Recent Events
- 01 May 2015 Clinical trials in Pancreatic cancer (Diagnosis) in USA (unspecified route) (NCT02399137)
- 01 Nov 2012 Clinical trials in Solid tumours (Diagnosis) in USA (NCT01733004)